Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. | MicrobiomeTrials← Back to trialsNCT04655365
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2022-03-22Est. Completion: 2025-11-01
Enrollment target: 30 participants Locations- CHUM, Montreal, Quebec, Canada
- CUSM, Montreal, Quebec, Canada
- CHU de Québec-Université Laval, Québec, Quebec, Canada
- CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada
Other microbiome trials you might be interested in
Bipolar Disorder Type I With Mania
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mani…
Glendale, United StatesEst. completion Jun 13, 2028
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients …
Birmingham, United StatesEst. completion Dec 31, 2026
Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplat…
Mobile, United StatesEst. completion Sep 30, 2027